Remestemcel-L-rknd

→ Srishti Gupta took over as CEO of Idorsia last summer, but the job is open again as chairman Jean-Paul Clozel kicks off another search. Idorsia’s shares dropped more than 13% on the Swiss exchange when the news broke on Monday. Gupta was called up from the board of directors to replace André Muller , who retired in July 2025 after just a year in the top spot. During Muller’s brief tenure, Idorsia came up empty on a proposed licensing deal for Tryvio , but the FDA gave the green light for its updated label , saying the blood pressure medicine didn’t need a REMS requirement. → George Eliades hopes to once again give a bounce to Jazz Pharmaceuticals , the oncology and neuro drugmaker that he left in 2024. Eliades is returning to the Irish and US biopharma under his previous title of chief transformation officer. He played a different tune for the past two years, serving as CEO of Mythic Therapeutics , but that bet fizzled out due to lackluster interest from investors in the clinical-stage ADC startup. Now he’s returning to a revamped Jazz to “help accelerate our next phase — sharpening our focus, strengthening execution, and ensuring we’re positioned to deliver meaningful impact for patients and their families,” according to a LinkedIn post. Since his departure in the spring of 2024, Jazz welcomed a new CEO, acquired Chimerix for a now- approved brain tumor treatment, inked the highest priority review voucher sale in a decade, and continued to expand its epilepsy pipeline . → Andy Nixon wrote about his departure from Boehringer Ingelheim on LinkedIn and posted a photo holding a cool going-away present: a Gibson guitar. Nixon spent the last five years as global head of biotherapeutics discovery research at the German pharma giant and had a 17-year career with Dyax . “The unexpected gift of the guitar perfectly highlighted what I’ve always valued during my time at Boehringer: being seen and appreciated as a complete person,” Nixon said, adding, “The genuine appreciation shown at my recent farewell event made leaving a much harder step than I anticipated.” → Purple Biotech ’s Gil Efron will step aside in August after four years as CEO and eight years overall. Efron was elevated to president and CFO in July 2021 and succeeded Isaac Israel as CEO a year later. The Israeli cancer biotech’s lead asset is a trispecific antibody for solid tumors called CAPTN-3 . Efron will stay on the board of directors. → Amphista Therapeutics CSO Louise Modis will now be taking over the company from retiring CEO Antony Mattessich , marking another female chief exec in the biotech circle. Modis joined the UK molecular glue biotech in 2023 after a gig as CSO at Mogrify . Before that, she had a seven-year stint at GSK and an eight-year run with Boehringer Ingelheim. Besides Modis’ appointment, Amphista also announced Patrick Kelly as CMO, having served in the same role at Forma Therapeutics , where he helped lead development of olutasidenib . → Korsana Biosciences , the latest startup out of biologics shop Paragon Therapeutics , has secured a CFO with IPO experience. Mark Vignola departed the CFO post at Terns Pharmaceuticals last winter, months before the drug developer ditched its obesity plans to go all in on cancer. Korsana doesn’t appear to be in immediate need of a finance whiz: The company raised a massive $150 million launch round in the fall of 2025, but waited until last month to unveil its Alzheimer’s ambitions that are eerily similar to Roche ’s late-stage program that penetrates the blood-brain barrier. → AbbVie ’s new head of M&A comes from GSK’s search and evaluation team. Garrett Rhyasen has jumped from the UK pharma giant, which is undergoing a CEO transition, to the Chicago-area drugmaker as VP of business development and acquisitions. Rhyasen is joining one of the most active BD teams in industry. AbbVie is digesting about 30 transactions worth $8 billion over the past two years, as noted by finance chief Scott Reents at Leerink ’s healthcare conference in Miami last week. → Harbour BioMed has named Jenny Xie as chief scientific officer for immunology and head of global external innovation for the Hong Kong-listed biotech with operations across China, Europe and the US. Xie was previously head of discovery immunology at Bristol Myers Squibb , where she spent the past 20 years and worked on “tolerance induction, immune reset and tissue repair,” with tools such as T cell engagers, according to her LinkedIn bio. Harbour has built a suite of partnerships in immunology, including with Xie’s longtime former employer and AstraZeneca . → Australian biotech Mesoblast has welcomed Teresa Montagut as its first head of clinical development and medical affairs. Montagut spent more than five years with Regeneron and had been global head of early pipeline studies in oncology, as well as head of medical affairs for investigator-sponsored studies of gastrointestinal and genitourinary conditions. Mesoblast wants to expand the label for its graft-versus-host disease treatment Ryoncil , the first-ever mesenchymal stromal cell therapy to receive an FDA approval . → We’ve got a few promotions to discuss, starting at Neurocrine . Andrew Ratz has been bumped up to chief technical operations officer after a year as SVP of drug development, delivery and device. He had an assortment of roles over 28 years at Eli Lilly , including SVP, delivery, device and connected solutions. Neurocrine’s Ingrezza is already approved for tardive dyskinesia and for chorea in patients with Huntington’s disease, but the San Diego biotech said in December that the drug flopped in a Phase 3 study for dyskinetic cerebral palsy. → Molecular glue specialist Monte Rosa Therapeutics said in its Q4 update that it has promoted its drug discovery leader Magnus Walter to chief technology officer, and Andrew Funderburk to chief investor relations and strategy officer. Walter is a longtime Lilly veteran who then worked for AbbVie as head of discovery chemistry, screening biology and operations. Funderburk joined Monte Rosa in 2024 as SVP, investor relations and strategic finance. Back in September, Novartis shelled out $120 million upfront for its second molecular glue deal with Monte Rosa in as many years. → Ajay Nirula has catapulted to president of Recludix Pharma and will continue to lead R&D, while the San Diego biotech has also promoted Catherine Bovenizer to CFO. Bovenizer held this position at Renova Therapeutics before she jumped to Recludix in 2020, and she had been SVP of finance and business operations since 2022. Peer Review told you about Nirula’s appointment as head of R&D in 2024, ending an eight-year run with Lilly. Recludix has been dosing healthy volunteers for a Phase 1 study of its Sanofi – partnered STAT6 inhibitor REX-8756 , good for a $20 million milestone payment. → IsomAb has a new CEO : Philip Brainin will now be steering the ship of the UK biotech, succeeding Jackie Turnbull . Brainin spent eight years on the medical side of things in Region Hovedstaden and previously was with Sound Bioventures , where he helped advise companies including Boost Pharma , VarmX and AnaCardio . Besides Brainin, IsomAb has also swapped out chairman Paul Edwards , who will remain on the board, with Anker Lundemose . → Cambridge, UK-based Alchemab Therapeutics has recruited Ulrich Wendt as CBO, ending a 25-year career with Sanofi in numerous capacities. He was global head of business development for the French pharma’s immunology & inflammation franchise for the past six years. Alchemab’s ALS candidate ATLX-1282 is at the heart of a licensing deal with Lilly that could be worth as much as $415 million. → Bispecific antibody developer Bambusa Therapeutics has welcomed Todd James as CFO. James was SVP, corporate affairs and investor relations at Viridian and from 2015-21 he was with Acceleron , where he helped secure more than $1 billion in financing. Bambusa was founded by BioNTech veterans Shanshan Xu and Helmut Jeggle and collected $140 million in Series A financing last year. The money will be used to fund clinical- and early-stage candidates, including dermatology and respiratory drugs BBT001 and BBT002 . → Early cancer detection company ClearNote Health has rolled out Jeffrey Venstrom as CMO. Ventstrom served in the same role at cancer screening company Grail , which last week announced that its CEO Bob Ragusa was retiring . Besides Ventstrom, ClearNote also hired Daniel Black as general manager of international markets, Jeremy Bennett as head of marketing, and promoted Irene Hsieh to VP of regulatory affairs and quality assurance. → Besides collecting $40 million this week, Mestag Therapeutics has also brought on Lindsey Rolfe as CMO and Pascal Merchiers as chief development officer. Rolfe served in the same role at both radiotherapy company 3B Pharmaceuticals and Clovis Oncology , where she helped secure marketing approvals in the US and Europe for Rubraca in ovarian and prostate cancer. Meanwhile, Merchiers has served in roles at Commit Biologics , Oncurious , Roche-acquired Tusk Therapeutics and Galapagos . The cash injection will help fund Mestag’s Phase 1 trial, slated to start in mid-2026, which will evaluate its candidate MST-0312 in cancer. → Virginia-based CDMO Phlow has plucked up Dawn Von Rohr as COO. Von Rohr joins the team after a stint as life sciences division president of Pace Life Sciences . Von Rohr had a long career at Mallinckrodt , ending a 22-year run with the company with her role as VP and general manager, global APIs. Last July, Phlow picked up $37 million in a Series C raise, looking to expand its API and key starting material manufacturing capacity in the US. → One of the industry’s longest-tenured investors, Frazier Life Sciences , has a fresh face in its biotech-building shop. Mansi Shinde is now VP of company creation at the firm. She was in corporate development roles at Nvelop Therapeutics and then carried on those duties when it merged with Chroma Medicine to become nChroma . Shinde helped form new biotech companies during a couple-year stint at 4:59 , the incubator unit of 5AM Ventures . She will be based in Frazier’s Boston office alongside colleagues Lauren Mifflin and Joe Cabral . The Frazier ecosystem is massive, with more than $5 billion in capital spread across both venture-backed startups and publicly traded life sciences companies. → Vertex Ventures has lost managing director Christine Brennan to another life sciences investor. Brennan departed the Temasek – backed firm to return to the corporate venture capital and large pharma strategy side of the industry. This week, she joined Johnson & Johnson Innovation , or JJDC , as a partner in the healthcare giant’s Cambridge office. As Brennan wrote in a LinkedIn post , she has “huge shoes to fill” in succeeding Marian Nakada , who left in September after more than a dozen years working on investing strategy at one of the oldest corporate venture arms in existence. Brennan has worked in CVCs before, having spent multiple years at Merck and Novartis’ units. → Royalty Pharma is in Peer Review for the second time this month as the royalty aggregator poaches a bulge bracket banker to help expand its portfolio. Greg Butz , Bank of America ’s global co-head of healthcare investment banking, will become EVP of partnering and investments at Royalty. The firm added a head of Asia this spring, plucking Kenneth Sun from Morgan Stanley . Meanwhile, Royalty said five-year company veteran Chris Hite is now its chair of partnering and investments. The Citi alum just picked up a board seat at Vera Therapeutics . → CSL Behring’s Korean subsidiary has recruited Se-eun Hwang as its new manager. Hwang was previously general manager of Biogen Korea and held roles at Abbott Korea and JW Pharmaceutical . Earlier this week, CSL announced that its hemophilia B gene therapy Hemgenix was temporarily out of stock , warning that some patients would experience delays in treatment. → Synthetic biology company Antheia has picked up Chris Savile as VP, business development and partnerships. Savile spent six years as CEO of Willow Biosciences , which sold its operating subsidiary in 2025 to become Evolutia Bio , while the rest of the company rebranded as Atlas Energy Corp and pivoted to international oil and gas royalty. Savile also previously held roles at Intrexon and Codexis . Antheia, which is partnered with Ginkgo Bioworks , hauled in $56 million in a Series C financing round last year to commercialize its API product thebaine , boost its US capacity and expand into Singapore. → Stockholm-based pediatric skeletal disease biotech Boost Pharma has enlisted Elaine Jones as chair of its board. Jones succeeds Ingelise Saunders , who will remain on the board. Jones’ résumé is stacked with board seats, including at CytomX , NextCure and Gritstone bio . Now led by former Galecto CEO Hans Schambye , Boost is developing a cell therapy for osteogenesis imperfecta, a rare bone disease with no approved treatments. → Radiopharma biotech Convergent Therapeutics has added former Y-mAbs CEO Michael Rossi to its board of directors. Rossi’s 30-year experience in radiopharmaceuticals through his previous roles — including Mirion Technologies , Advanced Accelerator Applications and Jubilant Radiopharma — will help the company and its radioantibody candidate CONV01-α , which is finishing up its Phase 2 trial in metastatic castration-resistant prostate cancer. → Muna Therapeutics CEO Rita Balice-Gordon has joined the board of directors at Lundbeck . Balice-Gordon started with Muna in 2020 as CSO before taking the top exec spot the next year. Under her leadership, Muna forged a pact with GSK in Alzheimer’s in 2024. Earlier this month, Lundbeck CEO Charl van Zyl told Endpoints News’ Zach Brennan that the company would not be forging a “most favored nation” deal with the White House, but instead would participate in one of the CMS pilots.

2026年3月6日，日本厚生劳动省正式批准两款基于诱导多能干细胞（iPSC）的疗法上市。这不是普通的监管动态——这是人类历史上首次有监管机构对通用型iPSC疗法按下商业化绿灯。同日，美国Vertex Pharmaceuticals公布了一项让糖尿病患者社群沸腾的数据：其干细胞疗法的12名受试者中，有11人在治疗后减少或完全停用了外源性胰岛素。三件事同时发生，不是巧合。干细胞治疗，这个曾被贴上"炒作"标签的领域，正在以坚实的临床数据重新站上舞台中央。 三个技术路线，各有胜负 干细胞治疗并非单一技术，而是三条并行的发展路径。每条路径都在2025至2026年间交出了答卷。间充质干细胞（MSC）：老将新功 这条路最"老"，但2024年底在美国实现历史性突破。 2024年12月18日，美国FDA批准了Ryoncil（通用名remestemcel-L）上市，用于治疗激素难治性的急性移植物抗宿主病。这是FDA历史上首个获批的MSC疗法。III期临床试验（编号NCT02336230）显示，54名儿童患者接受治疗后，第28天的客观缓解率达到69%，而历史对照组仅为45%。该疗法定价为单次输注19.4万美元，完整疗程约155万美元。 在中国，2025年1月2日，国家药品监督管理局附条件批准了艾米迈托赛注射液上市，用于14岁以上激素治疗失败的急性移植物抗宿主病。CDE受理号为CXSS2400062，研发历时超过十年。iPSC：日本率先破局 iPSC是近年来资本市场的"心头好"，但商业化始终是难题。2026年3月的日本批准打破了僵局。 日本厚生劳动省此次批准的两款iPSC产品分别针对帕金森病和重症心力衰竭，均采用"附条件限期批准"制度，有效期7年。 此前，住友制药一项发表在《Nature》上的研究显示，7名帕金森病患者接受iPSC来源的多巴胺神经前体细胞移植后24个月，5人的运动功能显著改善，多巴胺分泌量平均提升44.7%。 在中国，iPSC赛道已有近40家企业布局，其中约11家进入临床阶段。进展最快的是睿健医药，其NouvNeu001产品已于2025年4月启动帕金森病II期临床试验，这是全球首个进入临床II期的通用型iPSC细胞产品。脐带MSC：中国的"主战场" 这是中国企业的"主战场"。据行业统计，中国目前已有超过30个干细胞药物获得临床试验批件，其中约63%为脐带MSC路线。 脐带MSC的优势在于取材便利、细胞年轻活性高、免疫原性低，且中国企业在此领域布局最为密集。劣势在于批间一致性控制较难，疗效与骨髓MSC相比缺乏头对头数据。一笔账：患者到底要花多少钱 干细胞疗法的商业化，有一道绕不过去的坎——价格。 中国已上市五款CAR-T产品定价： 阿基仑赛注射液（120万元/针）、瑞基奥仑赛注射液（129万元/针）、伊基奥仑赛注射液（116.6万元/针）、纳基奥仑赛注射液（99.9万元/支）、泽沃基奥仑赛注射液（115万元/针）。以上均未纳入国家基本医保。 CAR-T贵的原因在于它是"活药物"——需要提取患者自身的T细胞，在体外进行基因改造后再回输，无法标准化批量制造。出路：按疗效付费与商业保险 复星凯特于2024年1月推出中国首款"按疗效付费"方案：患者若未达完全缓解，最高可返还60万元。 2025年12月，国家医保局发布了首版《商业健康保险创新药品目录》，将五款CAR-T产品全部纳入，这是CAR-T首次进入商业保险覆盖范围。上海、北京、杭州、长沙、广州等地已有多款惠民保产品将CAR-T纳入保障。 从全球视野看，美国早在2019年便建立了CAR-T的Medicare报销制度，医院支付标准为每次40万至50万美元。日本则将Temcell纳入国家医保，患者自付比例根据年龄和收入档次不同，通常在10%至30%之间。三个科室：神经、肿瘤、心血管神经科：阿尔茨海默病和帕金森病      2025年3月，一项发表在《Nature Medicine》（PMID: 40065171）上的研究让医学界对MSC治疗阿尔茨海默病刮目相看。这项名为CLEAR MIND的IIa期临床试验纳入49名轻度阿尔茨海默病患者，结果显示：接受高剂量MSC治疗的患者39周后，全脑萎缩速度减缓了48.4%，海马体萎缩速度减缓了61.9%，且未出现与治疗相关的严重不良事件。 帕金森病方面进展更为密集。BlueRock Therapeutics（拜耳旗下）研发的Bemdaneprocel于2025年1月获得FDA批准直接进入确证性III期临床试验（编号NCT04802733，试验名exPDite-2），这是全球首个以干细胞疗法治疗帕金森病进入注册III期的研究。日本则更为激进，直接批准了Amchepry的上市申请。肿瘤科：CAR-T扎堆，适应症扩展才是关键       CAR-T的竞争已白热化。中国五款产品全部靶向CD19，适应症集中于淋巴瘤和白血病。目前各企业正将CAR-T向自身免疫疾病（如系统性红斑狼疮）和实体瘤方向扩展，这被视为下一阶段的主战场。心血管科：心衰和心肌梗死      日本批准的心肌细胞片疗法ReHeart针对缺血性心肌病导致的重症心力衰竭。Vertex的糖尿病疗法VX-880也计划向糖尿病心肌病等心血管并发症扩展。一道监管题：双轨制下的中国答案 中国的干细胞监管，走的是一条独特的双轨道路。 药品路径由国家药品监督管理局主管，企业需按照完整的药物研发流程申报，包括GLP安全性评价、GMP生产规范和GCP临床试验。医疗技术路径由国家卫生健康委员会主管，医疗机构可在内部开展体细胞治疗。 双轨制的初衷是为不同成熟度的产品提供适配的监管通道，但也带来了一些灰色空间——部分企业以"医疗技术"名义开展临床治疗，向患者收取费用，却规避了药品审批的严格规范。 政策意图明确：让有核心技术的企业走药品路径规范化发展，让缺乏合规能力的企业逐步退出。行业普遍预期，约80%的现有细胞治疗企业可能面临退出或转型压力。一个结论：爆发期已至，但别急着乐观 综合各方数据，有几个结论是清晰的。 一、技术路线之争尚未分出胜负 iPSC有日本背书，MSC有欧、美、中三国获批产品，脐带MSC在中国IND数量最多。三条路线将并存，各自占据不同适应症和市场份额。 二、2026年是明确的商业化拐点年份 日本iPSC产品上市、Vertex糖尿病疗法冲刺上市、Lomecel-B的阿尔茨海默病数据发表——这些事件集中出现，不是偶然。 三、中国市场的支付困境正在缓慢解围 商保目录纳入CAR-T是标志性事件，但其实际覆盖效果仍取决于各地惠民保的落地执行。 四、规模化生产仍是行业最大的技术瓶颈 iPSC的批间一致性、MSC的GMP标准化、细胞制品的长期储存——这些问题不解决，商业化规模就难以真正放大。 干细胞治疗的未来，不是"会不会来"的问题，而是"以什么价格、什么速度、惠及哪类患者"的问题。而这些问题的答案，正在2026年逐一书写。 本报告数据来源包括：Vertex Pharmaceuticals公告（2026年3月16日）、BlueRock Therapeutics新闻稿（2025年1月13日）、《Nature Medicine》（2025年4月，PMID:40065171 ）、日本厚生劳动省公告（2026年3月6日）、国家药品监督管理局及CDE公开信息、各企业公告。市场规模数据来自前瞻产业研究院、中研普华等第三方报告。如有疏漏，敬请指正。